Overcoming 5 barriers to process automation in PV.
Q2 - 2020
With more and more safety data to capture, and a window of just 15 days to assess and report serious adverse events to health authorities, the case for automating the most labour-intensive aspects of pharmacovigilance (PV), is strong. So, what is holding companies back from investing in process transformation?
Peter Kohut, Director of Drug safety at Arriello, explores the main hurdles preventing greater automation of PV data capture processes within life sciences firms, and suggests a way forward...